Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIPHENY: Sepiapterin for Long-Term Neurocognitive Outcomes in Children With PKU
NCT06302348Phase 3Recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Mar 2024
- Primary completion
- Feb 2031
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of sepiapterin in phenylketonuria (PKU), sponsored by PTC Therapeutics, Inc.. Started Mar 2024; status: recruiting.
02
Drugs
sepiapterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT06302348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06302348.